
CASE REPORT

Open Access



Inês Barreto^{1*}, Francisca Godinho Oliveira¹, Sofia Carvalho Barreira^{2,3} and João Rodrigues Inácio^{4,5}

Abstract

Background Epipericardial fat necrosis (EFN) is a benign and self-limited condition of unknown cause with a good prognosis, usually affecting otherwise healthy patients. Clinically, it presents with severe acute left pleuritic chest pain, often leading the patient to the Emergency Room (ER).

Case presentation A 23-year-old male, smoker (5 pack-years), was evaluated in the ER due to left pleuritic chest pain, worsening with deep breathing and Valsalva maneuver. It was not associated with trauma and did not present other symptoms.

The physical examination was unremarkable. The arterial blood gases while breathing room air and the laboratory tests, including D-dimers and high-sensitivity cardiac Troponin T, were normal. The chest radiograph, electrocardiogram, and transthoracic echocardiogram showed no abnormalities.

A computed tomography (CT) pulmonary angiogram showed no signs of pulmonary embolism but depicted at the left cardiophrenic angle a focal 3 cm ovoid-shaped fat lesion with stranding and thin soft tissue margins, consistent with necrosis of the epicardial fat, which was confirmed by magnetic resonance (MRI) of the chest.

The patient was medicated with ibuprofen and pantoprazole, with clinical improvement in four weeks. At a twomonth follow-up, he was asymptomatic and presented radiologic resolution of the inflammatory changes of the epicardial fat of the left cardiophrenic angle on chest CT. Laboratory tests revealed positive antinuclear antibodies, positive anti-RNP antibody, and positive lupus anticoagulant. The patient complained of biphasic Raynaud's phenomenon initiated five years ago, and a diagnosis of undifferentiated connective tissue disease (UCTD) was made.

Conclusions This case report highlights the diagnosis of EFN as a rare and frequently unknown clinical condition, which should be considered in the differential diagnosis of acute chest pain. It can mimic emergent conditions such as pulmonary embolism, acute coronary syndrome, or acute pericarditis. The diagnosis is confirmed by CT of the thorax or MRI. The treatment is supportive and usually includes non-steroidal anti-inflammatory drugs. The association of EFN with UCTD has not been previously described in the medical literature.

*Correspondence: Inês Barreto inesscbarreto@gmail.com Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/lublicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Keywords Epipericardial fat necrosis, Chest pain, CT, MRI, Undifferentiated connective tissue disease

Background

Epipericardial fat necrosis (EFN), also known as pericardial fat necrosis or epicardial fat necrosis, is a rare and self-limiting condition usually occurring in otherwise healthy patients. It presents with acute pleuritic chest pain, which can mimic emergent conditions such as pulmonary embolism, acute coronary syndrome, or acute pericarditis [1–4].

The diagnosis can be made with chest computed tomography (CT), which typically demonstrates a round or ovoid encapsulated mediastinal fat-containing lesion in the cardiophrenic space, with thin soft tissue density margins [2, 5]. On magnetic resonance (MRI), there is a focal fatty lesion with increased signal in T2 fluid sensitive sequences in the acute phase [5].

The treatment is usually supportive and includes nonsteroidal anti-inflammatory drugs and the prognosis is good [1, 6].

Case presentation

The authors present a case of a 23-year-old Caucasian male, current smoker with five pack-years smoking history, with sporadic consumption of inhaled cannabis. He had a history of bilateral tonsillectomy and septoplasty.

The patient presented to the Emergency Room (ER) complaining of severe acute left pleuritic chest pain, worsening with deep inspiration and Valsalva maneuver. There was no history of chest trauma, fever, cough, sputum, wheezing, hemoptysis, or constitutional symptoms. He did not present any recent illness in the month that preceded the current complaint.

On physical examination, he was apyretic, eupneic breathing room air, with peripheral oxygen saturation of 96%, blood pressure 102/54 mmHg, and heart rate of 77 bpm. Cardiac and pulmonary auscultation were normal. The patient's body mass index (BMI) was 19.26 kg/ m^2 (weight: 71.0 kg; height: 1.92 m).

The arterial blood gases while breathing room air and the laboratory tests (including the complete blood count, kidney function, ionogram, and liver enzymes) were normal, being of note: D-dimers 0,37 ug/mL [normal range (NR): 0.0-0.5 ug/mL]; high-sensitivity cardiac Troponin T (hs-cTnT) <3 ng/L [NR: < 14 ng/L]; c-reactive protein (CRP) 0.470 mg/dL [NR: < 0.5 mg/dL]; erythrocyte sedimentation rate (ESR) 4 mm [NR: < 10 mm]. The viral panel, including human immunodeficiency virus (HIV), coxsackievirus, cytomegalovirus, Epstein-Barr virus, and hepatitis B and C virus, was negative. The chest radiograph presented no pulmonary consolidation, pneumothorax, or pleural effusion. The electrocardiogram presented sinus rhythm, heart rate of 65 bpm, with no signs of myocardial ischemia. The transthoracic echocardiogram showed normal size of the left ventricle, normal wall thickness, normal left ventricular function, with no regional wall motion abnormalities, no valvular abnormalities, no pericardial effusion or thickening, and no evidence of acute or chronic myocarditis.

A CT pulmonary angiogram showed no pulmonary embolism or vascular abnormalities. However, it depicted at the left cardiophrenic angle a focal 3 cm ovoid-shaped fat lesion with stranding and thin soft tissue margins, consistent with necrosis of the epicardial fat (Fig. 1A-C





Fig. 1 A – Normal chest radiograph; B and C – Contrast-enhanced chest CT reformatted axial and sagittal oblique images of the mediastinum demonstrate an ovoid-shaped mediastinal fat lesion with soft tissue stranding, consistent with necrosis of the epicardial fat at the left cardiophrenic angle (white arrows). D – Chest MRI sagittal oblique fluid sensitive T2 sequence image shows a fatty lesion with increased signal (edema) stranding in the left cardiophrenic angle (white arrow)

and Supplementary Material – Files 1, 2 and 3). The lungs, the pleura and the pericardium were normal.

Chest MRI demonstrated a 3 cm fatty lesion with increased T2 signal in the left cardiophrenic angle consistent with focal edema (Fig. 1D and Supplementary Material – Files 4 and 5).

The patient was medicated with ibuprofen 600 mg twice daily and pantoprazole 40 mg once daily, with symptomatic improvement after four weeks. A chest CT follow-up was performed two months after and confirmed the resolution of the inflammatory changes of the epicardial fat of the left cardiophrenic angle (Fig. 2B).

Laboratory tests at the two-month follow-up appointment revealed positive antinuclear antibodies (titer of 1/1280, with a speckled nuclear pattern, AC-5) and a positive anti-RNP antibody (>6438.0 UQ). In addition,



the lupus anticoagulant was positive, with a negative anticardiolipin and negative anti-beta-2-glycoprotein. All antiphospholipid antibodies were negative at the 12-week reassessment. The ESR, CRP, creatine phosphokinase, aldolase, complement C3 and C4 fractions, immunoglobulins and the urine analysis were normal.

Lung function tests presented normal spirometry, plethysmography, and alveolo-capillary diffusing capacity for carbon monoxide.

When further asked about other current or previous systemic symptoms, the patient complained about biphasic Raynaud's phenomenon initiated five years ago. He had no history of digital or oral ulcers, arthralgias, myalgias, muscle weakness, rash, photosensitivity, alopecia, dysphagia, dyspnea, or fever.

The patient was referred to a Rheumatology consult to assess a possible mixed connective tissue disease (MCTD). The nail fold videocapillaroscopy presented nonspecific microangiopathic abnormalities. The chest CT images did not show interstitial lung disease (ILD). A diagnosis of undifferentiated connective tissue disease (UCTD) with biphasic Raynaud's phenomenon was made, and the patient was medicated with aminaphtone 75 mg twice daily with clinical improvement of Raynaud's phenomenon. The patient is under follow-up for other manifestations such as synovitis and myositis, which could mean a differentiation into a MCTD in a patient with high anti-RNP antibody titers. A timeline highlighting the patient's clinical presentation and most relevant complementary exams findings is presented in Fig. 3.




Fig. 3 Timeline highlighting the patient's clinical presentation and most relevant complementary exams findings

Discussion and conclusions

This case highlights the diagnosis of EFN as a rare and frequently unknown medical condition, which should be considered in the differential diagnosis of acute chest pain in otherwise healthy patients [1].

Initially described in 1957 by Jackson et al. [7], EFN is thought to be related to an inflammatory process in the mediastinal fat surrounding the heart, affecting equally males and females [1]. It presents as severe acute pleuritic chest pain, ipsilateral to the lesion, usually on the left side, which may radiate to the neck, shoulder, upper arm, axilla, or back [4]. EFN can present with syncope, tachycardia and dyspnea that can mimic emergent conditions frequently leading the patient to the ER, such as pulmonary embolism, acute coronary syndrome, acute aortic syndrome, or acute pericarditis [1, 4, 8]. Cough and fever have never been reported in association with EFN [4].

A pericardial friction rub may be present on physical examination, and some patients may have tenderness to palpation over or near the precordium [1, 4]. The laboratory tests, including inflammatory markers, myocardial necrosis markers, D-dimer, and the electrocardiogram (ECG), are usually normal, and the viral panel is negative [1]. Occasionally, the ECG may show tachycardia and nonspecific ST or T-wave changes [4]. Transthoracic and transesophageal echocardiography may show an ovoid, solid pericardial mass [4].

The chest radiograph is nonspecific and is usually normal in the first 48-72 hours, after which there may be seen a juxtacardiac opacity near the cardiophrenic angle on the side of the chest pain, located anteriorly and usually merging with the cardiac silhouette, with or without a pleural effusion [1, 2, 8]. Chest CT is the preferred modality for diagnosing EFN, localising the abnormality in cardiophrenic space, and density measurements allowing confident characterisation of abnormal epicardial fat [1, 2, 5]. Chest CT typically demonstrates a round or ovoid encapsulated mediastinal fat-containing lesion with thin soft tissue density margins, and inflammatory changes of fat stranding and thickening of the adjacent epicardium [2]. Pleural effusion and adjacent subsegmental lung atelectasis can also be identified at the time of diagnosis [2, 4]. Findings on MRI include a focal fatty lesion with increased signal in T2 fluid sensitive sequences in the acute phase [5]. Gallium scintigraphy may show increased gallium uptake in the pericardial fat [4].

The treatment is usually supportive and includes nonsteroidal anti-inflammatory drugs. The pain is usually severe, may persist for several weeks, and can recur with less intensity for up to a year, but the prognosis is good [1, 6]. The differential diagnosis includes pericardial lipoma, pericardial liposarcoma, thymolipoma, and diaphragmatic hernia. Although the pathogenesis of EFN is unclear, some predisposing factors have been identified, such as trauma, ischemia related to acute epicardial fat torsion, high positioned pericardial fat, obesity, hemorrhagic necrosis due to increased thoracic pressure related to Valsalva maneuver, pre-existing structural abnormality of the adipose tissue, such as lipoma or hamartoma [1, 4, 8]. The association of EFN with rheumatologic conditions has not been previously established in the scientific literature.

The density values on CT and MRI signal characteristics allow a confident diagnosis of a fat lesion with edema in the acute setting [4]. If there is persistence of symptoms, persistence or growth of soft tissue and fat abnormalities on follow-up imaging studies, it may be impossible to distinguish between a benign and malignant fatty tumor, in which case surgical intervention may be indicated to confirm the diagnosis [4]. Some patients underwent exploratory thoracotomy after extensive nondiagnostic workups, presenting an inflammatory mass involving the parietal pericardial fat, whose histopathology showed resemblance to analogous conditions, such as epiploic appendagitis and fat necrosis in the omentum or breast [4]. In early phases, there is a central focus of necrotic fat cells surrounded by macrophages with neutrophilic infiltration, and in latter phases, there is also marked fibrosis. Calcifications may be seen. Removal of the lesion always leads to remission of symptoms [1, 4]. However, considering the characteristic clinical and radiological presentation and its benign course, a clinical diagnosis and supportive treatment should be privileged, reserving thoracic surgery only when the patient presents severe untreatable pain or unusual imaging findings [2, 4]. A follow-up chest CT or MRI 4 to 8 weeks after the acute presentation is recommended to confirm the expected healing [1, 2, 4].

Although only a few cases of EFN have been published in the literature, suggesting it is an infrequent diagnosis, recent case series suggest that it might be more prevalent than previously thought and may frequently be underdiagnosed [1, 2]. It is considered a benign self-limited condition, but in our case, EFN presented in a patient subsequently diagnosed with UCTD, which, to our current knowledge, has not been previously described, warranting clinical awareness of this potential association in this population. Rheumatologic conditions such as systemic lupus erythematosus (SLE) and UCTD have been linked to an increased risk of thrombosis, to which factors such as inflammation, endothelial dysfunction, and antiphospholipid antibodies, especially lupus anticoagulant, play a significant role [9-17]. The authors hypothesize that this prothrombotic status might be a predisposing cause leading to EFN in this patient, although further research is needed.

Abbreviations

BMI	Body mass index
CRP	C-reactive protein
CT	Computed tomography
ECG	Electrocardiogram
EFN	Epipericardial fat necrosis
ER	Emergency room
ESR	Erythrocyte sedimentationrate
HIV	Human immunodeficiencyvirus
hs-cTnT	High-sensitivity cardiac TroponinT
ILD	Interstitial lung disease
MCTD	Mixed connective tissuedisease
MRI	Magnetic resonance
NR	Normal range
NT-proBNP	N-terminal pro b-typenatriuretic peptide
SLE	Systemiclupus erythematosus
UCTD	Undifferentiated connective tissue disease

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12872-023-03349-x.

Additional file 1. Contrast-enhanced chest CT axial, sagittaland reformatted sagittal obliqueclip videos demonstrating an ovoid-shaped mediastinal fat lesion with soft tissue stranding, consistent with necrosis of the epicardial fat at the left cardiophrenic angle.

Additional file 2. Chest MRI sagittal (File 4) and sagittal oblique (File 5) fluid sensitive T2 sequence clip videos showing a fatty lesion with increased signal (edema) stranding in the left cardiophrenic angle.

Acknowledgements

This case was presented at a conference presentation.

Authors' contributions

IB participated in the treatment of the patient, data collection, writing and revision of the manuscript. FGO participated in the writing and revision of the manuscript. SCB participated in the treatment of the patient, writing and revision of the manuscript. JRI participated in data collection, writing and revision of the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

All data and materials are available for sharing if needed. The corresponding author should be contacted for access to the data.

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Pulmonology Department, North Lisbon University Hospital Centre (CHULN), Lisbon Medical Academic Centre (CAML), Avenida Professor Egas Moniz 1649-035, Lisbon, Portugal. ²Rheumatology Department, North Lisbon University Hospital Centre (CHULN), Lisbon Medical Academic Centre (CAML), Lisbon, Portugal. ³Rheumatology Research Unit, Institute of Molecular Medicine (IMM), Faculty of Medicine of the University of Lisbon, Lisbon Medical Academic Centre (CAML), Lisbon, Portugal. ⁴Radiology Department, North Lisbon University Hospital Centre (CHUNL), Lisbon Medical Academic Centre (CAML), Lisbon, Portugal. ⁵Radiology Clinic, Faculty of Medicine of the University of Lisbon, Lisbon Medical Academic Centre (CAML), Lisbon, Portugal.

Received: 17 August 2022 Accepted: 13 June 2023 Published online: 22 June 2023

References

- KdSGiassi, Costa AN, Bachion GH, Apanavicius A, Filho JRP, Kairalla RA, et al. Epipericardial fat necrosis: an underdiagnosed condition. Br J Radiol. 2014;87(1038):20140118. https://doi.org/10.1259/bjr.20140118.
- Pineda V, Cáceres J, Andreu J, Vilar J, Domingo ML. Epipericardial fat necrosis: radiologic diagnosis and follow-up. Am J Roentgenol. 2005;185(5):1234–6. https://doi.org/10.2214/AJR.04.1310.
- Haq S, Wilson MP, Manca D. Epipericardial fat necrosis: an uncommon self-limiting cause of pleuritic chest pain. CMAJ. 2019;191(50):E1378–81. https://doi.org/10.1503/cmaj.190703.
- Fred HL. Pericardial fat necrosis: a review and update. Tex Heart Inst J. 2010;37(1):82–4.
- Rafiee MJ, Khaki M, Haririsanati L, Fard FB, Chetrit M, Friedrich MG. MRI findings of epipericardial fat necrosis: as a rare cause of acute chest pain in a healthy man. Radiol Case Rep. 2022;17(7):2488–91. https://doi.org/10. 1016/j.radcr.2022.04.013.
- Carvalho NB, Lopes e Silva NP, Pereira PPN, Morganti AV, Silva SL, Rodrigues AS. Epipericardial fat necrosis. An important differential diagnosis of chest pain. Int J Cardiovasc Imaging. 2017;30:91–4.
- Jackson RC, Clagett OT, McDonald JR. Pericardial fat necrosis: report of three cases. J Thorac Surg. 1957;33(6):723–9.
- Lacasse MC, Prenovault J, Lavoie A, Chartrand-Lefebvre C. Pericardial fat necrosis presenting as acute pleuritic chest pain. J Emerg Med. 2013;44(2):e269-71. https://doi.org/10.1016/j.jemermed.2012.05.032.
- 9. Bashal F. Thrombosis in Rheumatological Diseases. In: Almoallim H, Cheikh M, editors. Skills in Rheumatology. Singapore: Springer; 2021. https://doi.org/10.1007/978-981-15-8323-0_12.
- Skjelland M, Zamani M, Hetlevik S, Lilleby V, Halvorsen B, Skagen K. Increased endothelial activation in patients with mixed connective tissue disease. J Stroke Cerebrovasc Dis. 2020;29(2):104563. https://doi.org/10. 1016/j.jstrokecerebrovasdis.2019.104563.
- Alpert MA, Goldberg SH, Singsen BH, Durham JB, Sharp GC, Ahmad M, Madigan NP, Hurst DP, Sullivan WD. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation. 1983;68:1182–93. https://doi.org/10.1161/01.CIR.68.6.1182.
- 12. Soltesz P, Bereczki D, Szodoray P, et al. Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease. Arthritis Res Ther. 2010;12:R78. https://doi.org/10.1186/ar2999.
- Perinbasekar S, Chawla K, Rosner F, Depestre M. Complete recovery from renal infarcts in a patient with mixed connective tissue disease. Am J Kidney Dis. 1995;26(4):649–53. https://doi.org/10.1016/0272-6386(95) 90603-7. PMID: 7573021.
- Mavrogeni S, Sfikakis PP, Dimitroulas T, Koutsogeorgopoulou L, Karabela G, Katsifis G, Stavropoulos E, Gialafos E, Spiliotis G, Kolovou G, Kitas GD. Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance. Inflamm Allergy Drug Targets. 2015;14(2):111–6. https://doi.org/10.2174/18715 28114666160105112758. PMID: 26728774.
- Laczik R, et al. Impaired endothelial function in patients with undifferentiated connective tissue disease: a follow-up study. Rheumatol. 2014;53(11):2035–43. https://doi.org/10.1093/rheumatology/keu236.
- 16. Targońska-Stępniak B, Wielosz E, Majdan M. Microangiopathic antiphospholipid syndrome (MAPS) in the course of undifferentiated connective

tissue disease. JMS. 2014;83(1):81–3. Available from: https://jms.ump.edu. pl/index.php/JMS/article/view/49. Cited 2022 Jul. 15.

 Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost. 1996;76(6):916–24 PMID: 8972011.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

